Statement Of Cash Flows [Abstract]

ERYTECH Pharma S.A. - Filing #858938

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Income taxes paid (refund), classified as operating activities
3,000 EUR
2,000 EUR
EUR
Cash flows from (used in) operating activities
31 764 EUR
56 770 EUR
51 720 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
37 630 EUR
EUR
83,000 EUR
Purchase of property, plant and equipment, classified as investing activities
85,000 EUR
298,000 EUR
1 139 EUR
Purchase of intangible assets, classified as investing activities
EUR
EUR
2,000 EUR
Cash flows from (used in) investing activities
38 127 EUR
345,000 EUR
1 475 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
EUR
34 631 EUR
118,000 EUR
Proceeds from issuing other equity instruments
EUR
EUR
12,000 EUR
Proceeds from borrowings, classified as financing activities
3 081 EUR
12 157 EUR
27 134 EUR
Repayments of borrowings, classified as financing activities
3 081 EUR
EUR
62,000 EUR
Payments of lease liabilities, classified as financing activities
1 545 EUR
1 702 EUR
1 615 EUR
Interest paid, classified as financing activities
223,000 EUR
374,000 EUR
326,000 EUR
Cash flows from (used in) financing activities
1 768 EUR
44 712 EUR
25 449 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
495,000 EUR
1 656 EUR
981,000 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
5 090 EUR
10 747 EUR
28 727 EUR
Cash and cash equivalents
38 789 EUR
33 699 EUR
44 446 EUR
73 173 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.